Co-Authors
This is a "connection" page, showing publications co-authored by BORJE S ANDERSSON and APOSTOLIA MARIA TSIMBERIDOU.
Connection Strength
2.549
-
Autologous engineered T cell receptor therapy in advanced cancer. Hum Vaccin Immunother. 2023 12 15; 19(3):2290356.
Score: 0.931
-
T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors. J Hematol Oncol. 2021 06 30; 14(1):102.
Score: 0.785
-
Synergistic Cytotoxicity of Histone Deacetylase and Poly-ADP Ribose Polymerase Inhibitors and Decitabine in Breast and Ovarian Cancer Cells: Implications for Novel Therapeutic Combinations. Int J Mol Sci. 2024 Aug 26; 25(17).
Score: 0.244
-
Synergistic cytotoxicity of histone deacetylase and poly-ADP ribose polymerase inhibitors and decitabine in pancreatic cancer cells: Implications for novel therapy. Oncotarget. 2024 Jun 03; 15:361-373.
Score: 0.241
-
Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy. J Hematol Oncol. 2023 10 25; 16(1):108.
Score: 0.231
-
First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors. J Immunother Cancer. 2024 Jul 22; 12(7).
Score: 0.061
-
Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer. Cancer Immunol Res. 2023 07 05; 11(7):925-945.
Score: 0.056